-
Phil Rivers Technology Secures IND Approval for PR00012 from NMPA’s CDE
•
Beijing-based Phil Rivers Technology Co.,Ltd, a high-tech platform company incubated by the Institute of Computing Technology, Chinese Academy of Sciences, has announced receiving Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for its Category 1 drug, PR00012. Phase I…
-
Phil Rivers Tech Raises RMB 100 Million for Computational Medicine Push
•
Beijing-based Phil Rivers Tech, a computational medicine-empowered drug developer, reportedly raised close to RMB 100 million (USD 14.9 million) in a Series A financing round. The funding was led by Insight Capital and Tenaya Capital, with participation from Highthink Med. The proceeds will be used for the upgrade of its…
